NCT02519920

Brief Summary

This study was to test an appropriate dose of fluorescein sodium which can provide high image quality to ensure endoscopy examination and have no yellow dye in the skin by a randomized blinded controlled trial.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
63

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Apr 2015

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2015

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 3, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 11, 2015

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

October 20, 2015

Status Verified

September 1, 2015

Enrollment Period

8 months

First QC Date

August 3, 2015

Last Update Submit

October 19, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Different ratios of high resolution CLE images among four different fluorescein sodium dose groups(0.01ml/kg,0.02ml/kg,0.05ml/kg,0.1ml/kg)

    six months

Secondary Outcomes (1)

  • Different degrees of skin yellow dye of patients in four different fluorescein sodium dose groups(0.01ml/kg,0.02ml/kg,0.05ml/kg,0.1ml/kg)

    six months

Study Arms (4)

group 1

EXPERIMENTAL

This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.

Drug: fluorescein sodium 0.01ml/kg

group 2

EXPERIMENTAL

This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.

Drug: fluorescein sodium 0.02ml/kg

group 3

EXPERIMENTAL

This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.

Drug: fluorescein sodium 0.05ml/kg

group 4

ACTIVE COMPARATOR

This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.

Drug: fluorescein sodium 0.1ml/kg

Interventions

fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin

group 1

fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin

group 2

fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin

group 3

fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin

group 4

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Only those with normal mucosa and minor gastritis from 18 were included.
  • patients with aged 18 years to 80 years
  • patients with normal mucosa and minor gastritis
  • willing to provide informed consent

You may not qualify if:

  • serious coagulopathy dysfunction, severe cardiopulmonary disease, bronchial asthma, liver and kidney dysfunction, allergy to fluorescein, pregnancy women or breast feeding.
  • patients with peptic ulcer, gastric cancer, remnant stomach, acute serious gastritis were also excluded.
  • unwilling to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Gastroenterology, Qilu Hospital, Shandong University

Jinan, Shandong, 250012, China

RECRUITING

MeSH Terms

Interventions

Fluorescein

Intervention Hierarchy (Ancestors)

FluoresceinsSpiro CompoundsHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsXanthenesHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsPolycyclic Compounds

Study Officials

  • Yanqing Li, PhD.MD

    Department of Gastroenterology,Qilu Hospital,Shandong University

    STUDY DIRECTOR

Central Study Contacts

Yanqing Li, PhD.MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vice president of Qilu Hospital

Study Record Dates

First Submitted

August 3, 2015

First Posted

August 11, 2015

Study Start

April 1, 2015

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

October 20, 2015

Record last verified: 2015-09

Locations